Amgen’s $3.5 Billion Notes Offering

Shearman & Sterling represented BofA Merrill Lynch, Goldman Sachs & Co. LLC, Barclays and Mizuho Securities as joint book-running managers and representatives of the underwriters in connection with Amgen’s registered offering of U.S.$3.5 billion of investment grade notes, consisting of $300 millon Senior Floating Rate Notes due 2019, $300 million Senior Floating Rate Notes due 2020, $700 million 1.900% Senior Notes due 2019, $700 million 2.200% Senior Notes due 2020 and $1.5 billion 2.650% Senior Notes due 2022.

Amgen is a global biotechnology company that discovers, develops, manufactures and delivers human therapeutics based on advances in cellular and molecular biology.

The Shearman & Sterling team was led by partners Robert Evans (Picture) (New York-Capital Markets) and Chris Forrester (Menlo Park-Capital Markets) and associates Nathan Mee (San Francisco-Capital Markets) and Yian Huang (Menlo Park-Capital Markets). Other key members of the team included partner Laurence Crouch (Menlo Park-Tax), counsel Emily Griffen (San Francisco-Litigation), and associates Benjamin Petersen (Menlo Park-IP) and Emalie Sundale (Menlo Park-Tax).


Involved fees earner: Robert Evans – Shearman & Sterling; Christopher Forrester – Shearman & Sterling; Nathan Mee – Shearman & Sterling; Yian Huang – Shearman & Sterling; Laurence Crouch – Shearman & Sterling; Emalie Sundale – Shearman & Sterling; Emily Griffen – Shearman & Sterling; Benjamin Petersen – Shearman & Sterling;

Law Firms: Shearman & Sterling;

Clients: Barclays Bank; Bank of America Merrill Lynch; Mizuho Securities;



Author: Ambrogio Visconti